A Randomized Non-Comparative Phase II Study of Nivolumab or Nivolumab/BMS-986205 alone or combined with Intravesical BCG in Patients with BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Non-muscle Invasive Bladder Cancer
-
Age: Between 18 - 100 Years
-
Gender: Female
-
Other Inclusion Criteria:
1. Pathologically confirmed High-Risk, Non-Muscle Invasive Bladder Cancer 2. BCG-Unresponsive (BCG (Bacille Calmette Guerin) treatment is defined as at least 2 courses of BCG)
You may not be eligible for this study if the following are true:
-
1. Patients with an active, known or suspected autoimmune disease. 2. Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.